Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Obesity drug enthusiasm can continue in 2024: Mizuho's Jared Holz
06:40pm, Wednesday, 27'th Dec 2023
Mizuho's Jared Holz joins 'Fast Money' to talk enthusiasm surrounding obesity drugs and if that can endure into 2024.
Pharmaceutical stocks to watch in 2024
02:53am, Monday, 25'th Dec 2023
As the new year beckons, the pharmaceutical industry is poised for more developments, building on advances made in 2023. The industry harbors several companies leading the way in groundbreaking innova
Will Novo Nordisk Be Worth More Than Meta Platforms by 2030?
07:10am, Saturday, 23'rd Dec 2023
Demand for Novo Nordisk's weight-loss products has become so significant that the company is investing billions into building more capacity. Meta Platforms has been one of the best-performing stocks t
Novo Nordisk, FDA warn of fake Ozempic
01:01pm, Friday, 22'nd Dec 2023
The U.S. Food and Drug Administration has seized thousands of units of fake Ozempic, the agency said Thursday, warning that some counterfeit units of the Novo Nordisk NVO, -0.15% diabetes drug may sti
7 Low-Volatility Stocks for Stable Growth in 2024
02:11pm, Thursday, 21'st Dec 2023
At first glance, targeting low-volatility stocks to buy for stable growth might seem too cautious. Yet, in the investment world, keeping tabs on volatility is imperative and a key indicator of risk.
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
09:45am, Thursday, 21'st Dec 2023
The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.
09:30am, Thursday, 21'st Dec 2023
Investing early in an emerging field can sometimes lead to outsize returns. Medicines that extend life spans are going to be big someday.
Why Novo Nordisk Stock Was Up on a Down Day for the Market
04:58pm, Wednesday, 20'th Dec 2023
An article in "The New York Times" pointed out that Ozempic and Wegovy's active ingredient could have other healing properties. It could help with ovarian disorders, for example, or even help combat a
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
11:17am, Wednesday, 20'th Dec 2023
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
09:46am, Wednesday, 20'th Dec 2023
Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
Why Novo Nordisk Stock Is Moving Higher Today
10:53am, Monday, 18'th Dec 2023
The overall stock market rise likely helped boost Novo Nordisk's shares. A top Indian online marketplace is also working to halt illegal sales of Novo's weight loss drug Wegovy.
5 Big Drug Stocks That May Continue to Outperform in 2024
10:31am, Monday, 18'th Dec 2023
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
09:15am, Monday, 18'th Dec 2023
Understanding what's hot and what's not is key to investing in biopharma. Drugs like Ozempic are going to continue being very popular next year.
5 Non-U.S. Stocks to Buy as Wall Street Fires on All Cylinders
09:01am, Monday, 18'th Dec 2023
We have selected five high-flying non-U.S. companies that have strong potential for 2024. These are: NVO, NTES, TM, PDD, STLA.
Novo Nordisk owner channels some of Wegovy windfall into respiratory diseases
08:09am, Monday, 18'th Dec 2023
The Novo Nordisk (NYSE:NVO) Foundation, which has the controlling holding of Novo Nordisk, has announced an investment of around $265 million to establish a new initiative focused on enhancing vacci
